Ascendis Pharma (ASND) Looks at Decreased FY2025-26 Revenues - Cantor Fitzgerald

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $254.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented, "Management commentary suggests it is in late-stage labeling discussions. And the FDA has not requested any additional data. We assume manufacturing inspection has already occurred. What's also notable is that Ascendis was emphasizing the U.S. opportunity in achondroplasia due to TransCon CNP's impact on comorbidities, which may explain the poor uptake of Voxzogo (CNP analog) in the U.S. Ascendis noted potential differentiation on TransCon CNP's label vs. Voxzogo's, particularly around hypotension and comorbidity benefits. The latter is key for U.S. patients. The Ph3 combination trial of TransCon CNP and TransCon hGH (Skytrofa) was aligned with the FDA, and 1-year linear growth should be the primary endpoint. The Agency is "open-minded" to the duration of treatment. Model update. We updated our model according to Ascendis' 3Q25 print. Due to lower-than-estimated revenue in 3Q25, EPS decreased. We updated our estimates in-line with the company's reported numbers, which decreased revenues in remaining 2025 quarter and FY 2025 and 2026. We slightly modified our OpEX estimates in 2026, in-line with the reported OpEx in 3Q 2025, which together with reduced revenue resulted in lower EPS in all 2026 quarters and the fiscal year. We maintain our 12-month Price Target of $254/sh."

For an analyst ratings summary and ratings history on Ascendis Pharma click here. For more ratings news on Ascendis Pharma click here.

Shares of Ascendis Pharma closed at $199.22 yesterday.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Axis Capital Limited Downgrades Landmark Cars (LANDMARK:IN) to Add (2)
• Axis Capital Limited Downgrades National Aluminium (NACL:IN) to Sell (4)